middle.news
How Will Noxopharm’s $2.6M Convertible Notes Fuel SOF-SKN Trial Progress?
3:28am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Will Noxopharm’s $2.6M Convertible Notes Fuel SOF-SKN Trial Progress?
3:28am on Saturday 30th of August, 2025 AEST
Key Points
36.5% increase in annual loss to $4.88 million
Progress on SOF-SKN™ first-in-human HERACLES clinical trial
Issued $2.6 million in convertible notes to sophisticated investors
Positive preclinical data from CRO-67 and Chroma platforms
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NOX
OPEN ARTICLE